| Trial ID: | L3535 |
| Source ID: | NCT00624767
|
| Associated Drug: |
Insulin (Recombinant Human Insulin)
|
| Title: |
A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus
|
| Interventions: |
DRUG: Insulin (recombinant human insulin)|DRUG: NovoLog
|
| Outcome Measures: |
Primary: To evaluate the effect on postprandial glycemic control of intranasal insulin compared to NovoLog, 4 hour Profile | Secondary: To evaluate the pharmacokinetics of intranasal insulin compared to NovoLog, 4 hour Profile
|
| Sponsor/Collaborators: |
Sponsor: Nastech Pharmaceutical Company, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-03
|
| Completion Date: |
2008-05
|
| Results First Posted: |
|
| Last Update Posted: |
2008-05-20
|
| Locations: |
Diabetes and Glandular Disease Research Associates, San Antonio, Texas, 78258, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00624767
|
